A medical device company, Melbourne-based Leica Biosystems produces three of the most recognised and reliable cancer diagnostic instruments. The company’s business model is anchored around international participation; 90 per cent of its products are exported and sell to 65 countries around the world.
Leica Biosystems is also a global leader in workflow solutions and the only company on the market providing instruments used from biopsy to diagnosis; this puts the company in a unique position to work on breaking down the barriers between these steps – shorter times between biopsy and diagnosis saves lives.
This success are grounded in the unique expertise of its Melbourne centre of excellence and in the commitment of its highly skilled teams to remain at the forefront of anatomical pathology.
Judges commented on the strong export performance of Leica Biosystems over the last 3 years. The application demonstrated the business’ commitment to continuous innovation and R&D to remain ahead of the curve.